Revenue
$60.44B
Gross Margin
+81.7%
Operating Margin
+23.7%
Net Margin
+17.2%
Income statement waterfall for AstraZeneca (AZN) — TTM through Q1 2026
Net income: $10.39B
Margin breakdown for AstraZeneca (AZN) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $60.44B | $60.44B |
| Cost of Revenue | −$11.07B | $49.37B |
| Gross Profit | $49.37B | $49.37B |
| Operating Expenses | −$35.05B | $14.31B |
| Operating Income | $14.31B | $14.31B |
| Other Income / Expense | −$1.40B | $12.91B |
| Pre-tax Income | $12.91B | $12.91B |
| Income Tax | −$2.52B | $10.39B |
| Net Income | $10.39B | $10.39B |
- Revenue$60.44B
- Cost of Revenue−$11.07B
- Gross Profit$49.37B
- Operating Expenses−$35.05B
- Operating Income$14.31B
- Other Income / Expense−$1.40B
- Pre-tax Income$12.91B
- Income Tax−$2.52B
- Net Income$10.39B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement